Disease | Tissue/cell type | Number | Upregulated gene | Â | Downregulated gene | Â | PMID/GEO ID | |
---|---|---|---|---|---|---|---|---|
Up | Down | Â | Â | Â | Â | Â | ||
A. Nuclear receptors have the tendency to be downregulated than being upregulated in rheumatoid arthritis | ||||||||
 |  |  |  |  | Fold* |  | Fold* |  |
 |  |  |  |  | ∆ |  | ∆ |  |
Rheumatoid arthritis | Synovial tissue | 3 | 9 | NR1H3 | 2.08 | NR1A1 | −20 | 24690414/GSE55235 |
NR1I1 | 2.12 | NR1C3 | −2.56 | |||||
NR3A1 | 2.59 | NR1D1 | −20 | |||||
 |  | NR2F1 | −2.94 | |||||
 |  | NR3C3 | −2 | |||||
 |  | NR3C4 | −2.22 | |||||
 |  | NR4A1 | −4.76 | |||||
 |  | NR4A2 | −10 | |||||
 |  | NR4A3 | −3.85 | |||||
B. Nuclear receptors are more downregulated than upregulated in metabolic diseases in humans | ||||||||
 |  |  |  |  | Fold** |  | Fold** |  |
 |  |  |  |  | ∆ |  | ∆ |  |
Family hypercholesterolemia | T cells | 7 | 11 | NR1B3 | 1.41 | NR1A1 | −1.3 | –/GSE6088 |
NR1C3 | 1.94 | NR1B1 | −1.22 | |||||
NR1I1 | 1.75 | NR1B2 | −1.72 | |||||
NR3C4 | 1.97 | NR1C1 | −1.72 | |||||
NR4A2 | 2.03 | NR1F1 | −2 | |||||
NR4A3 | 1.5 | NR1F2 | −1.79 | |||||
NR0B1 | 2.36 | NR1H3 | −1.28 | |||||
 |  | NR3B3 | −2.08 | |||||
 |  | NR3C1 | −1.22 | |||||
Family hypercholesterolemia | Monocytes | 10 | 12 | NR1B1 | 1.23 | NR1A1 | −2.27 | 19040724/GSE6054 |
NR1F3 | 2.38 | NR1B2 | −1.72 | |||||
NR1I1 | 1.31 | NR1C1 | −1.59 | |||||
NR2F6 | 2.61 | NR1F1 | −1.52 | |||||
NR3B2 | 1.33 | NR1H3 | −1.28 | |||||
NR4A1 | 1.94 | NR2A2 | −2.13 | |||||
NR4A2 | 2.06 | NR2C1 | −1.47 | |||||
NR5A1 | 2.1 | NR2C2 | −1.19 | |||||
NR6A1 | 1.62 | NR2E3 | −2.63 | |||||
NR0B1 | 2.02 | NR3A1 | −2 | |||||
 |  | NR3A2 | −1.79 | |||||
 |  | NR3C1 | −1.28 | |||||
Metabolic syndrome | Peripheral blood | 0 | 1 |  |  | NR4A3 | −1.54 | 21368773/GSE23561 |
Type 2 diabetes | Arterial tissue | 0 | 2 |  |  | NR1B2 | −1.28 | 22340758/GSE13760 |
 |  | NR3C3 | −1.12 | |||||
Type 1 diabetes | Peripheral blood mononuclear cell | 1 | 2 | NR3C4 | 1.2 | NR1F1 | −1.89 | –/GSE55100 |
 |  | NR4A3 | −1.2 | |||||
Morbidly obese | Adipose stem cells | 3 | 3 | NR4A1 | 8.06 | NR1A1 | −1.2 | 24040759/GSE48964 |
NR4A2 | 12.64 | NR1D1 | −1.2 | |||||
NR4A3 | 4.44 | NR2C2 | −1.25 | |||||
Morbidly obese | Human omental adipose tissue | 1 | 1 | NR4A2 | 3.5 | NR2B3 | −2.44 | 20678967/GSE15773 |
Homocysteine (100 μM) | Human aortic smooth muscle cells | 3 | 3 | NR2B3 | 1.2 | NR1H3 | −1.33 | 18602108/GSE9490 |
NR3A2 | 1.61 | NR2F2 | −1.7 | |||||
NR4A3 | 1.49 | NR4A2 | −1.24 | |||||
Hypertension | Carotid artery atheromatous plaques | 0 | 2 |  |  | NR1A2 | −2.04 | 23660665/GSE43292 |
 |  | NR3C3 | −2 | |||||
C. Nuclear receptors are significantly downregulated than upregulated in human aortic endothelial cells (HAECs) treated with oxidized low-density lipoproteins (Ox-LDLs) in a time-dependent manner | ||||||||
 |  |  |  |  | Fold* |  | Fold* |  |
 |  |  |  |  | ∆ |  | ∆ |  |
Treated with Ox-LDL for 6 h | HAEC | 4 | 3 | NR1I2 | 2.18 | NR1B2 | −3.57 | 19279231/GSE13139 |
NR2A2 | 3.8 | NR1F1 | −5.26 | |||||
NR3A2 | 3.04 | NR4A1 | −2.56 | |||||
NR5A2 | 4 | Â | Â | |||||
Treated with Ox-LDL for 12 h | 0 | 7 |  |  | NR1B1 | −2.86 | ||
 |  | NR1B2 | −5.56 | |||||
 |  | NR1F1 | −2.86 | |||||
 |  | NR1H4 | −5.88 | |||||
 |  | NR2A2 | −2.04 | |||||
 |  | NR3A1 | −2.94 | |||||
 |  | NR3C3 | −2.33 | |||||
Treated with Ox-LDL for 24 h | 5 | 7 | NR1C1 | 2.24 | NR1B1 | −2.56 | ||
NR1I1 | 2.01 | NR1B2 | −2.17 | |||||
NR3A2 | 5.09 | NR1B3 | −2.04 | |||||
NR3B2 | 2.34 | NR1H4 | −4.55 | |||||
NR5A2 | 5.81 | NR1I2 | −2.5 | |||||
 |  | NR2A2 | −2.13 | |||||
 |  | NR2F6 | −4.55 |